artículo académico

• Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.  American Journal of Obstetrics and Gynecology.  215:212.e1-212.e15. 2016
• Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.  Journal of Infectious Diseases.  213:939-947. 2015
• Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial.  BMJ Journal.  351. 2015
• Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials.  The Lancet Oncology.  16:775-786. 2015
• Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.  Journal of the National Cancer Institute.  108. 2015
• Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing.  Journal of the National Cancer Institute.  107. 2015
• Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.  Vaccine.  33:2141-2151. 2015
• Mipartoxin-I, a novel three-finger toxin, is the major neurotoxic component in the venom of the redtail coral snake Micrurus mipartitus (Elapidae).  Toxicon.  60:851-863. 2012